Introduction
Clinical research is crucial for advancing medical knowledge and patient care, and phase I trials represent the first stage of the clinical development of a new drug, in which a small group of healthy volunteers or -in selected fields including oncology and for antiretroviral drugs -patients receive the drug. The primary objective is to evaluate the drug's safety and tolerability (1) .
Examples include a study in which the anti-CD28 monoclonal antibody TGN1412 was administered in March 2006 to healthy volunteers, which resulted in multiorgan dysfuncion in some of them (13) . More recently, the BIA 10-2474 trial in January 2016 led to severe adverse events in 5 participants, 1 with a fatal outcome (14, 15) .
In Italy, prior to the disastrous BIA trial, the need to increase the level protection for participants in phase I trials, together with the will to ensure high ethical standards and the quality of the data collected for the marketing authorization, led the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA) to issue, on June 19, 2015 , the Determination 809/2015 (16) , which states the minimum mandatory requirements for research units and laboratories to be qualified for the conducting of phase I trials.
The AIFA Determination 809/2015 is composed of a General Section and of 3 Appendices. The General Section explains how each unit and laboratory should provide a selfcertification attesting to compliance with the requirements. The AIFA Determination's Appendix 1 provides the guidelines for the unit organization, defines the characteristics of the facilities, building, services accessibility, business continuity plan, and type of medical equipment in case of emergency, and also specifies the role and competencies of the trial expert personnel within an organizational chart. Appendix 1 also specifies the requirements for phase I trials with highrisk drugs. The AIFA Determination's Appendix 2 sets out the requirements for laboratories involved in any test conducted for phase I. It defines the laboratory organization; the personnel competencies; the management of biological samples; and the characteristics of equipment, reagents, computers and of the quality systems. Appendix 3 lists all of the standard operating procedures (SOPs) that units and laboratories should have in place.
Starting from July 9, 2016, the Determination was in force and mandatory for any phase I trial conducted in Italy. With regard to the Italian research situation, as described in the AIFA's "15 th National Report on the Medicinal Clinical Research" (17) , the relatively recent history of early-phase research of our country is reflected (18) . In fact, phase I trials represent a mean 8.2% of all trials evaluated from 2011 to 2016: from a minimum of 41 to a maximum of 69 trials per year. In 2015, nearly all of the approved phase I trials (97.1%) were addressed to patients and less to 3% to healthy volunteers.
Among the several aspects which may have contributed to such low numbers in phase I research, the lack of dedicated phase I facilities might have reduced the appeal for pharmaceutical companies to conduct early-phase research in Italy. In this context, the new AIFA Determination could also contribute to making Italy a more attractive market for phase I trials.
Before its coming into force, we investigated how Italy was preparing to implement the changes introduced by the Determination.
Our choice to conduct the survey among the personnel (investigators and clinical research coordinators) of institutions involved in oncology research was driven by the fact that, according to the AIFA reports (17, 19) , oncology represents the main therapeutic area of Italian research.
Methods

Survey design
A Web-based Google survey was created and addressed to 80 main Italian centers involved in clinical research. The survey was designed to cover the core aspects of the Determination, especially those historically more critical and more often not fully implemented or lacking in some centers. The survey consisted in 20 questions in 4 main domains. The first domain was dedicated to general questions to get a picture of each site's characteristics and the type of clinical research conducted; the second and the third domains captured information on the phase I unit and laboratories, and the fourth explored the status of development of SOPs.
The full set of questions is reported in the Supplementary Appendix (available online at www.tumorijournal.com/ -Survey questions).
Survey invitation
Clinical investigators, clinical research coordinators (CRCs), ethics committee staff and personnel from the medical management of sites involved in oncology research were surveyed from March 1 st to May 1 st , 2016. They were contacted by e-mail through the main Italian oncology networks and scientific societies involved in research, and through the Italian Group of CRCs and Data Managers (GIDM). All data were anonymous, and participation was voluntary.
Answering the survey took around 10 minutes, and the link was active for 60 days. Data received from clinical investigators and CRCs from the same site were accounted as a single reply.
Data analysis
Given the descriptive nature of the survey, we did not formally estimate a required sample size. Instead, we sought to obtain data from at least 50% of the centers contacted. All data were analyzed in the first week of May, and the conclusions here reported refer to the number of self-certified centers as of June 1 st , 2016.
Results
Of the 80 invited centers, a total of 46, working in 42 different units, replied to the survey (57.2% of the sample). Thirty-seven units were oncology units (88.1%), 26 (61.9%) operated in public or university hospitals and 16 (38.1%) belonged to the Scientific Institutes for Research and Care (IRCCS). The majority of the units were for adult oncohematology (76.2%), 11.9% were for pediatric oncohematology and the remaining 7.1% were not oncology units.
Responses from the medical management and ethics committees were also received (4.8%). These responses were mainly from CRCs or data managers (71.8%), while 21.4% were clinical investigators who work in centers where more than 40 trials are ongoing (about 45% of the sites). With regard to participation in phase I trials, about 55% of the centers (23 of 42) had conducted between 1 and 5 trials in the last 5 years, 11.9% more than 7, while 28.6% had not participated in any (Tab. I). While none of the sites had ever conducted first-in-human (FIH) trials with healthy volunteers, most had participated to non-FIH phase I trials in patients (33.3%).
The involvement in phase I independent research was limited: the majority of institutions (57.1%) were not involved in any phase I trials promoted by noncommercial sponsors, while 35.7% had conducted from 1 to 2 studies, and only 2 centers (4.8%) more than 7 (Tab. I).
Exploring the overall requirements for centers and laboratories dedicated to phase I trials, we found that less than 10% of the sites, at the time of the survey, fully met the required conditions for self-certification, while most (71.4%) were working to implement them. Less than 5% of the centers claimed to be not interested in conducting phase I research (Tab. II).
According to the AIFA Determination's Appendix 1 ( Article 1, paragraph m), the Determination imposes several requirements for the storage of trial documents, such as in archives equipped with fire protection, antiflood, antirodent and antiparasite systems. In many of the sites (40.5%), the required archives were already present, and in about 30%, their implementation was deemed easy to achieve (Tab. II).
To be qualified to conduct phase I trials promoted by independent sponsors, the Determination states that the site's organizational chart must include a clinical trial quality team (CTQT), whose characteristics are defined in the AIFA CTQT document of April 2008 titled "Minimum Requirement for Participation in the AIFA Project on Quality in Noncommercial Clinical Trials" (20) .
Our survey highlighted the fact that in 38.1% of the centers, the CTQT was already present, while in 23.8% it was not and another 38.1% were working to implement it. Moreover, the Determination requires that each unit must be provided with a certified clinical trial monitor and an auditor, according with the Ministerial Decree of November 15, 2011 (21) . Thirty-one percent of the sites claimed to already be compliant, with the presence of a qualified monitor, and 14.3% of them also confirmed the presence of a certified auditor. About 20% (21.4%) and a third of the sites, were planning to open an internal position for monitor and auditor, respectively. The remaining sites were planning to outsource the monitor (4.8%) and the auditor (26.2%), while many of them either expect to make use of a sponsor's monitor (26.2%) or identify in the auditor presence a potential issue (14.3%) (Tab. II).
The required professional who acts as the link person between the site and the sponsor or the regulatory authorities and who is responsible for managing the study data was identified by most (78.6%) as the CRCs or data managers who were already in charge to cover these aspects.
The mandatory GCP training that the Determination requires for research personnel is already provided by most sites, internally (35.7%) or externally (40.5%) (Tab. II).
The Determination also covers and establishes specific criteria for conducting high-risk-drug phase I trials. Of the respondents, 69.0% declared they were already compliant with this request (Tab. II), while 31.0% were not interested in these types of study.
The third domain of our survey was dedicated to examining how and to what extent, the sites' laboratories were working to fulfill the AIFA Determination's Appendix 2 requirements. About 50% of the sites considered their own laboratories already adequate or affirmed that only a minor effort was required to satisfy them (16.7%), while for 33.4%, compliance with this requirement would depend on the local budget or will be unlikely to be achieved in a short time (Tab. III). The required SOP for the conducting of phase I trials were already in place in the majority of sites (57.1%), or only small adaptations were needed to be compliant. Thirty-one percent of sites were actively working to implement them, and 85.7% affirmed they had internal competencies for their development. Only a few (7.1% and 2.4%, respectively), were going to outsource the SOP implementation or will ask sponsors for support (Tab. IV).
Discussion
Our survey was designed to examine to what extent the major centers involved in oncology research were, or were working to be, compliant with the AIFA Determination 809/2015.
Our results highlighted that the specific personnel dedicated to clinical research, such as the CRCs, is more perceptive and aware of changes in regulation (22) than the investigators. Furthermore, it was not surprising that the majority of the sites (78.5%) are running from 11 to 100 ongoing trials and that, in last 5 years, more than 55% were involved in noncommercial early-phase research (40.5%). According to the answers we received, almost all of the sites were working to fulfill the AIFA Determination to be eligible for phase I studies (95.2%).
At time of data collection, the results of the survey confirmed that, whereas only a few units (9.5%) were already compliant with requirements, about 50% of their laboratories were completely adequate and in more than 57% of sites, specific SOP for clinical research were operative or close to being so.
The majority of noncompliant sites were working hard to be ready to be self-certified, facing critical issues such as the requirements for document storage, record keeping, activities of highly specialized personnel such as internal monitors and auditors, high-risk-drugs procedures and SOP development.
Independent research, mainly promoted by national and international oncology cooperative groups, plays an important role especially in rare tumors. Due to its noncommercial nature, early-phase independent research is essentially represented by phase Ib trials, and the possibility to keep conducting these will rely on the presence or early implementation of a dedicated CTQT.
Because our survey was conducted prior to the release on April 4, 2016, of the AIFA Determination 451/2016 (23) , in which the modality for self-certification of units and laboratories was detailed, we compared the results obtained with the number of units self-certified and recognized by AIFA after 1 year (24). The list of the self-certified centers, published on the Italian Medicines Agency website, suggests that this process was initially underestimated, since the first self-certifications were submitted near to the coming into force of the Determination.
In the first 4 months, 50.0% of the centers and laboratories applied for self-certification, with a peak in July (23.5%), suggesting that most of the centers interested in phase I conduction had already applied for certification (Fig. 1) . After 1 year from the beginning of the self-certification process, 98 units and laboratories had achieved their self-certification for phase I trials (data from AIFA website) (24) . Thirty-eight of these were public or private laboratories (38.8%), 44 were units only (44.9%) and 16 (16.3%) were units with internal laboratories. Of the 60 units, 34 (56.7%) were specific oncohematology units, 14 (23.3%) were generic units dedicated to phase I trials and 12 (20.0%) are not dedicated to oncology trials. The distribution of self-certified units and laboratories favored northern Italy over central and southern Italy (Fig. 2) .
This number of self-certified oncology units confirmed the results of our survey, indicating that most of them were ready to apply for phase I trial certification, and that in the near future we may expect a growing number of self-certifications. However, as per Determination 809/2015, 3 months should elapse for AIFA to confirm the certification, and sites and laboratories will be inspected by the AIFA GCP Inspection Activity Office to establish whether the requirements are maintained. Thus, in the future, the number of the qualified centers may change or be confirmed.
Study limitations
The major limitation of our study was the relatively small sample size and response rate (57.2%). In fact, consistent with how voluntary surveys are handled, we have analyzed only responses from sites interested in replying, and therefore we cannot exclude the possibility that other sites may be on track for achievement of the new requirements. Lastly, while we took care in designing a survey focused on the major innovations of the Determination, we may have missed other potentially important aspects. 
Conclusion
The AIFA Determination 809/2015 represented a turning point for phase I trials in Italy, as it required established standards for units and laboratories that want to conduct early-phase research. Although this survey was representative only of oncology research, it clearly highlighted how the Italian health system is working hard to achieve the required standards, even in a time of spending reviews in health care. Our results show that big efforts were made by centers in recent months to obtain qualifications for phase I, indicating that Italians are aware that compliance with the Determination will be crucial for their competitiveness on the European scene. The results suggest that in the near future most of the Italian oncology sites will be ready to apply for selfcertification leading to Italian institutions being highly qualified and reliable in conducting phase I research.
